UNSPSC 51384528: Ibuprofen sodium

This classification denotes a cyclooxygenase inhibitor with the molecular formula C13H17O2.Na.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RM1CE97Z4N, chemically known as hydratropic acid, p-isobutyl-, sodium salt but more generally known as ibuprofen sodium, which bears US NIH Compound Identifier 161696. European Medicines Agency schedules Ibuprofen sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21665.

Most nations, for tariff and trade purposes, schedule ibuprofen sodium under HS 29163990 and SITC 51379. As of Q4 2014, IBUPROFEN SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CC(C)CC1CCC(CC1)C(C)C(=O)[O-].O.O.[NA+].

UNSPSC 51384528 Ibuprofen sodium is a Commodity code that captures pharmaceutical products state and local governments procure for health and safety programs, though recent solicitations tagged under this code span a broader range of medications and pharmaceutical supply arrangements than ibuprofen alone. State and local buying under this code includes emergency medical countermeasures (naloxone), over-the-counter pharmaceuticals, generic multi-source drugs, and direct-to-manufacturer prescription fulfillment programs. Issuing bodies include county health departments, state health and human services agencies, and cooperative purchasing alliances that serve multiple jurisdictions. The Seminole County, Florida procurement for naloxone and drug deactivation systems exemplifies county-level emergency response procurement; the Texas Health and Human Services Commission's Therapeutic Pharmacy Initiative and Minnesota's MMCAP generic pharmaceutical RFP represent state-level and multi-state cooperative purchasing vehicles that aggregate demand across participating entities.

Recent activity concentrates in the Southeast and Upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs supporting its pharmacy benefit objectives. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a proposal deadline of March 26, 2026, requiring vendors to supply through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) with all products available by May 15, 2026 and a contract effective date of July 1, 2026.